(lp0
S'Cleveland BioLabs Announces Commencement of In Vivo Biocomparability Study Yahoo Finance - 21 hours ago BUFFALO, NY-- - Cleveland BioLabs, Inc.  today announced that the U.S. Food and Drug Administration  has completed its review of a side-by-side analytical comparison of two formulations of entolimod.Cleveland BioLabs, Inc.  Files An 8-K Other Events - Market ExclusiveCleveland Biolabs  to Begin In Vivo Bio-Comparability Study Following ... - StreetInsider.com'
p1
aS'Cleveland BioLabs shares rocket on progress of anti-radiation drug candidate Proactive Investors USA & Canada - 18 hours ago Shares in Cleveland BioLabs Inc  shot up over 53% in New York Monday as the FDA gave it the go-ahead for a biocomparability study on its candidate entolimod in non human primates.'
p2
aS'BUZZ-U.S. STOCKS ON THE MOVE- Arconic, MoneyGram, Cleveland BioLabs, OncoMed Nasdaq - 15 hours ago N&gt;, down 13.3 pct at $2.02 ** Tenet Healthcare &lt;THC.N&gt;, down 8.7 pct at $15.96 The top three percentage gainers on the Nasdaq &lt;.US STOCKS ON THE MOVE-Incyte, MoneyGram, Alere, OncoMed - Times of India'
p3
aS'Technical Levels in Review for Cleveland Biolabs Inc  Rives Journal - 15 hours ago Narrowing in on moving averages for Cleveland Biolabs Inc , the 200-day is at 1.82, the 50-day is 1.68, and the 7-day is resting at 1.65.'
p4
aS'Cleveland BioLabs Announces Webcast of Annual Meeting Yahoo Finance - Apr 11, 2017 BUFFALO, NY-- - Cleveland BioLabs, Inc.  today announced that the Company will webcast its 2017 Annual Meeting of Stockholders on April 21, 2017 at its headquarters in Buffalo, NY.'
p5
aS'Cleveland BioLabs Inc. CBLI  Wall Street Journal - Feb 11, 2011 Cleveland BioLabs Inc. CBLI . search. View All companies. AT CLOSE 3:50 PM EDT 03/31/17. $1.60 USD; 0.01 0.63%.'
p6
aS'Cleveland BioLabs Reports Second Quarter 2016 Financial Results and ... MarketWatch - Aug 15, 2016 BUFFALO, NY, Aug 15, 2016  -- BUFFALO, NY-- - Cleveland BioLabs, Inc. CBLI, +1.96% today reported financial results and development progress for the second quarter ended June 30, 2016.'
p7
aS'Premarket Gainers as of 9:05 am Seeking Alpha - 20 hours ago CBLI +37% on announcing that the U.S. Food and Drug Administration has completed its review of a side-by-side analytical comparison of two formulations of entolimod.'
p8
aS'Cleveland BioLabs Announces a $1.1 Million Cost Realignment With the ... Marketwired  - Oct 11, 2016 BUFFALO, NY-- - Cleveland BioLabs, Inc.  today announced that the Department of Defense  has modified its Joint Warfighter Medical Research Program  contract award number&nbsp;...'
p9
aS"Cleveland Biolabs  Reports Reverse Stock Split StreetInsider.com - Jan 27, 2015 Cleveland BioLabs, Inc.  today announced that at a special meeting of stockholders held on January 27, 2015, stockholders authorized the Company's Board of Directors to effect a reverse stock split of the Company's common stock at a ratio&nbsp;..."
p10
a.